Hormone therapy and age-related macular degeneration: the Women’s Health Initiative Sight Exam Study.

Kleins Lab // Publications // Jul 01 2006

PubMed ID: 16832022

Author(s): Haan MN, Klein R, Klein BE, Deng Y, Blythe LK, Seddon JM, Musch DC, Kuller LH, Hyman LG, Wallace RB. Hormone therapy and age-related macular degeneration: the Women’s Health Initiative Sight Exam Study. Arch Ophthalmol. 2006 Jul;124(7):988-92. PMID 16832022

Journal: Archives Of Ophthalmology (Chicago, Ill. : 1960), Volume 124, Issue 7, Jul 2006

OBJECTIVE To determine the effectiveness of treatment with conjugated equine estrogens (CEE) or with CEE combined with progestin (CEE + P) on age-related macular degeneration (AMD).

METHODS In an ancillary study to the Women’s Health Initiative clinical trial of hormone therapy, 4262 women 65 years and older underwent fundus photography for the determination of AMD. Participants were recruited from April 2000 to June 2002 at 21 clinical sites an average of 5 years after randomization. Participants were randomized to treatment with CEE, CEE + P, or placebo. Participants had been treated for an average of 5 years at the ophthalmic evaluation for AMD.

RESULTS The overall prevalence of any AMD was 21.0%. No association was found between CEE + P (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.75-1.11) or CEE alone (OR, 0.98; 95% CI, 0.78-1.25) and early-stage AMD. The CEE + P was associated with a reduced risk of soft drusen (OR, 0.83; 95% CI, 0.68-1.00) after adjustment for covariates and with a reduced risk of neovascular AMD (OR, 0.29; 95% CI, 0.09-0.92).

CONCLUSIONS Treatment with CEE alone or CEE + P does not affect early- or late-stage AMD. Treatment with CEE + P may reduce the risk of soft drusen or neovascular AMD.